Beijing Tiantan Biological Products Co., Ltd (SHA: 600161), a biopharmaceutical firm based in China, has declared its decision to discontinue a Phase III clinical study for its intravenous injection of cytomegalovirus human immunoglobulin (pH4). The company cited prevailing market conditions and internal strategic planning as the key factors influencing this termination.
The product in question, intended for the treatment of cytomegalovirus (CMV) and associated diseases in immunocompromised patients, including those undergoing hematopoietic stem cell transplantation, received approval to commence clinical trials in China back in December 2016. Up until this announcement, Tiantan had invested a substantial RMB 70.69 million into the development of this therapeutic candidate.- Flcube.com
